0.491
price down icon2.54%   -0.0128
 
loading
Schlusskurs vom Vortag:
$0.5038
Offen:
$0.5103
24-Stunden-Volumen:
134.77K
Relative Volume:
0.18
Marktkapitalisierung:
$17.94M
Einnahmen:
$45.91M
Nettoeinkommen (Verlust:
$-4.62M
KGV:
-3.5021
EPS:
-0.1402
Netto-Cashflow:
$-21.51M
1W Leistung:
-35.22%
1M Leistung:
-35.72%
6M Leistung:
-41.76%
1J Leistung:
-77.48%
1-Tages-Spanne:
Value
$0.4404
$0.5103
1-Wochen-Bereich:
Value
$0.3642
$0.602
52-Wochen-Spanne:
Value
$0.3642
$2.43

Equillium Inc Stock (EQ) Company Profile

Name
Firmenname
Equillium Inc
Name
Telefon
(858) 412-5302
Name
Adresse
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
EQ's Discussions on Twitter

Vergleichen Sie EQ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
EQ
Equillium Inc
0.491 17.94M 45.91M -4.62M -21.51M -0.1402
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Equillium Inc Stock (EQ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-28 Herabstufung Leerink Partners Outperform → Market Perform
2021-10-29 Fortgesetzt Stifel Buy
2021-09-15 Eingeleitet Cantor Fitzgerald Overweight
2020-07-14 Bestätigt H.C. Wainwright Buy
2020-07-10 Fortgesetzt Stifel Buy
2019-02-22 Eingeleitet SVB Leerink Outperform
Alle ansehen

Equillium Inc Aktie (EQ) Neueste Nachrichten

pulisher
Apr 01, 2025

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

Equillium Reports 2024 Financials and Clinical Milestones - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe

Mar 27, 2025
pulisher
Mar 17, 2025

Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 07, 2025

Equillium Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Feb 28, 2025

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Equillium stock rallies 26% on itolizumab study data - MSN

Feb 28, 2025
pulisher
Feb 21, 2025

Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

Feb 21, 2025
pulisher
Feb 12, 2025

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St

Feb 12, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq

Feb 10, 2025
pulisher
Feb 10, 2025

Healthy Upside Potential: Equillium Inc (EQ) - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium reports positive Phase 2 ulcerative colitis study data - MSN

Feb 10, 2025
pulisher
Feb 07, 2025

why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News

Feb 07, 2025
pulisher
Feb 07, 2025

Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com

Feb 07, 2025
pulisher
Feb 07, 2025

Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues

Feb 07, 2025
pulisher
Feb 07, 2025

UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK

Feb 07, 2025
pulisher
Feb 06, 2025

Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating - GuruFocus.com

Feb 06, 2025

Finanzdaten der Equillium Inc-Aktie (EQ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):